Abstract:Abstract Purpose Triple-negative breast cancer (TNBC) is a highly diverse group of disease, and clinical outcome of patients with TNBC is highly variable. Due to the heterogeneity of TNBCs, there is limited molecular signature routinely used for predicting the risk of disease recurrence and benefit of adjuvant chemotherapy. Our study aims to develop and validate a RNA signature, integrating messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs) together, for TNBC patients to improve risk stratification and avoid unnecessary adjuvant therapy. Methods Using transcriptome microarrays, we analyzed 33 paired TNBC and adjacent normal breast tissues, and identified 1,644 mRNAs and 1,047 lncRNAs which were differentially expressed between tumors and normal tissues. We further determined the expression of these mRNAs and lncRNAs in an additional 134 TNBC samples using transcriptome microarrays, and confirmed their associations with patients' recurrence-free survival (RFS). Using the LASSO Cox regression model, we built an integrated mRNA-lncRNA signature incorporating seven mRNAs and three lncRNAs. Prognostic and predictive accuracy of the signature was tested in the training set of 167 TNBC patients and further validated in an independent validation set of 143 TNBC patients. Results In the training set, we identified 36 mRNAs and 32 lncRNAs which were tumor-specific and significantly associated with patients' RFS. Using the LASSO Cox regression model, an integrated mRNA-lncRNA signature based on seven mRNAs (CCR4, CTSB, ERO1L, HIF1A, IGFR1R, SRD5A1 and TFF1) and three lncRNAs (n381928, n333541 and TCONS_I2_00013109-XLOC_I2_007048) was developed in the training set and subsequently validated in the validation set. Patients were classified to the high-risk (high risk of recurrence) and low-risk (low risk of recurrence) groups according to their scores in the signature. In the training set, multivariate analysis showed that the predicted high-risk group had higher risk of developing recurrent disease within five years of surgery than the low-risk patients (hazard ratio [HR] = 6.12, 95% confidence interval [CI] 2.76-13.56, P<0.001). In the validation set, the predicted high-risk group also had poorer RFS in multivariate analysis (HR = 5.09, 95% CI 1.82-10.96, P<0.001). Furthermore, analyzing the areas under the time-dependent receiver operating curve for five-year RFS, we proved the integrated mRNA-lncRNA signature had better prognostic value than the seven-mRNA-only signature and clinicopathological risk factors in both the training and validation sets. Finally, Cox proportional hazards models were utilized to test the interaction between adjuvant chemotherapy and different risk groups. Patients in the low-risk group had a more favorable response to adjuvant chemotherapy both in the training and validation sets. Conclusion The integrated mRNA-lncRNA signature is a reliable tool for predicting disease recurrence and benefit of adjuvant chemotherapy in TNBC patients. If further validated in larger population, it could facilitate patient counseling and individualize treatment of TNBC. Citation Format: Yizhou Jiang, Yi-Rong Liu, Ke-Da Yu, Xin Hu, Xiao-En Xu, Ling Yao, Zhi-Ming Shao. Prognostic and predictive value of an integrated mRNA-lncRNA signature in triple-negative breast cancer: A comprehensive transcriptome analysis [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-08-28.

Abstract 5681: Identification of dysregulated miRNAs involved in TNBC progression

RNA-sequencing and Microarray Data Mining Revealing: the Aberrantly Expressed Mrnas Were Related with a Poor Outcome in the Triple Negative Breast Cancer Patients

Abstract 1945: Identification of a miRNA/mRNA network driving non-small cell lung cancer (NSCLC) dissemination

Identification Of A Mirna/Mrna Network Driving Non-Small Cell Lung Cancer (Nsclc) Dissemination

Identification of Dysregulated Micrornas in Triple-Negative Breast Cancer (Review).

Abstract 3961: Identification of lncRNAs as potential novel therapeutic targets in triple negative breast cancer

Integration of single-cell and bulk transcriptome analyses unravels a macrophage-based gene signature for prognostication and treatment in triple-negative breast cancer

MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer

Exploring Specific Prognostic Biomarkers in Triple-Negative Breast Cancer.

Abstract 461: Dual-kinase targeted miRNA nanotherapy for the treatment of triple-negative breast cancer

Abstract 4726: Identification of efficacy biomarkers for therapies targeting miR-10b

MicroRNAs-mediated Cell Fate in Triple Negative Breast Cancers

Abstract 3198: Comprehensive Transcriptome Analysis Identifies Integrated Mrna-Lncrna Signature of Triple-Negative Breast Cancer Treated with Radiotherapy

Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer

Abstract P6-08-28: Prognostic and Predictive Value of an Integrated Mrna-Lncrna Signature in Triple-Negative Breast Cancer: A Comprehensive Transcriptome Analysis

Abstract 6800: The tumor progression mechanism of increasing CXCL16-CXCR6 pathway within the tumor microenvironment in TNBC

Abstract 4600: Phenotypic & functional diversity of tumor associated neutrophils in murine breast tumor models

Bioinformatic miRNA-mRNAs Analysis Revels to miR-934 as a Potential Regulator of the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer

Identification of Hub Genes and Upstream Regulatory Factors Based on Cell Adhesion in Triple-negative Breast Cancer by Integrated Bioinformatical Analysis

MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer

Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis